Sample Answer for NURS 6630 Week 7 Therapy for Patients With Schizophrenia Included After Question<\/strong><\/h2>\nWeek 7: Therapy for Patients With Schizophrenia<\/a><\/span><\/b>\u00a0<\/span><\/h3>\nAccording to the Schizophrenia and Related Disorders Alliance of America, approximately 3.5 million people in the United States are diagnosed with schizophrenia (n.d.), and it is one of the leading causes of disability. In practice, patients may present with delusions, hallucinations, disorganized thinking, disorganized or abnormal motor behavior, as well as other negative symptoms that can be disabling for these individuals. Not only are these symptoms one of the most challenging symptom clusters you will encounter, many are associated with other disorders, such as depression, bipolar disorder, and disorders on the schizophrenia spectrum. As a psychiatric nurse practitioner, you must understand the underlying neurobiology of these symptoms to select appropriate therapies and improve outcomes for patients.<\/span>\u00a0<\/span><\/p>\nThis week, as you examine antipsychotic therapies, you explore the assessment and treatment of patients with psychosis and schizophrenia. You also consider ethical and legal implications of these therapies.<\/span>\u00a0<\/span><\/p>\n![\"NURS](\"http:\/\/nursingassignmentcrackers.com\/wp-content\/uploads\/2024\/02\/Capture-7-2-300x84.png\")
NURS 6630 Week 7 Therapy for Patients With Schizophrenia<\/figcaption><\/figure>\nReference:<\/span>
\nSchizophrenia and Related Disorders Alliance of America. (n.d.).\u202f<\/span>About\u202f schizophrenia<\/span><\/i>.https:\/\/sardaa.org\/resources\/about-schizophrenia\/#:~:text=Quick%20Facts%20About%20Schizophrenia.%20Schizophrenia%20can%20be%20found,is%20one%20of%20the%20leading%20causes%20of%20disability<\/a><\/span>\u00a0<\/span><\/p>\nLearning Objectives<\/span>\u00a0<\/span><\/p>\nStudents will:<\/span><\/b>\u00a0<\/span><\/h2>\n\n- Assess client factors and history to develop personalized therapy plans for patients with insomnia<\/span>\u00a0<\/span><\/li>\n
- Analyze factors that influence pharmacokinetic and pharmacodynamic processes in patients requiring therapy for insomnia<\/span>\u00a0<\/span><\/li>\n
- Assess patient factors and history to develop personalized plans of antipsychotic therapy for patients<\/span>\u00a0<\/span><\/li>\n
- Analyze factors that influence pharmacokinetic and pharmacodynamic processes in patients requiring antipsychotic therapy<\/span>\u00a0<\/span><\/li>\n
- Synthesize knowledge of providing care to patients presenting for antipsychotic therapy<\/span>\u00a0<\/span><\/li>\n
- Analyze ethical and legal implications related to prescribing antipsychotic therapy to patients across the lifespan<\/span>\u00a0<\/span><\/li>\n<\/ul>\n
\u00a0<\/span><\/p>\nLearning Resources<\/span>\u00a0<\/span><\/p>\n\u00a0<\/span><\/p>\nRequired Readings<\/span><\/b>\u202f(click to expand\/reduce)<\/span><\/a>\u00a0<\/span><\/p>\n\u00a0<\/span><\/p>\nFreudenreich, O., Goff, D. C., & Henderson, D. C. (2016). Antipsychotic drugs. In T. A. Stern, M. Favo, T. E. Wilens, & J. F. Rosenbaum. (Eds.), <\/span>Massachusetts General Hospital psychopharmacology and neurotherapeutics<\/span><\/i>\u202f(pp. 72\u201385). Elsevier.<\/span>\u00a0<\/span><\/p>\n\u00a0<\/span><\/p>\nAmerican Psychiatric Association. (2019). <\/span>Practice guideline for the treatment of patients with schizophrenia<\/span><\/i>. https:\/\/www.psychiatry.org\/File%20Library\/Psychiatrists\/Practice\/Clinical%20Practice%20Guidelines\/APA-Draft-Schizophrenia-Treatment-Guideline.pdf<\/span><\/a>\u00a0<\/span><\/p>\n\ufffc<\/span>\u00a0<\/span><\/p>\nClozapine REMS. (2015). <\/span>Clozapine REMS: The single shared system for clozapine<\/span><\/i>. https:\/\/www.clozapinerems.com\/CpmgClozapineUI\/rems\/pdf\/resources\/Clozapine_REMS_A_Guide_for_Healthcare_Providers.pdf<\/span><\/a>\u00a0<\/span><\/p>\n\ufffc<\/span>\u00a0<\/span><\/p>\nFunk, M. C., Beach, S. R., Bostwick, J. R., Celano, C. M., Hasnain, M., Pandurangi, A., Khandai, A., Taylor, A., Levenson, J. L., Riba, M., & Kovacs, R. J. (2018). <\/span>Resource document on QTc prolongation and psychotropic medications<\/span><\/i>. American Psychiatric Association. https:\/\/www.psychiatry.org\/File%20Library\/Psychiatrists\/Directories\/Library-and-Archive\/resource_documents\/Resource-Document-2018-QTc-Prolongation-and-Psychotropic-Med.pdf<\/span><\/a>\u00a0<\/span><\/p>\n\ufffc<\/span>\u00a0<\/span><\/p>\nKay, S. R., Fiszbein, A., & Opler, L. A. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. <\/span>Schizophrenia Bulletin, 13<\/span><\/i>(2), 261\u2013276.\u202fhttps:\/\/doi.org\/10.1093\/schbul\/13.2.261<\/span><\/a>\u00a0<\/span><\/p>\n\ufffc<\/span>\u00a0<\/span><\/p>\nLevenson, J. C., Kay, D. B., & Buysse, D. J. (2015). The pathophysiology of insomnia. <\/span>Chest, 147<\/span><\/i>(4), 1179\u20131192. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4388122\/<\/span><\/a>\u00a0<\/span><\/p>\n\ufffc<\/span>\u00a0<\/span><\/p>\nMcClellan, J. & Stock. S. (2013). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. <\/span>Journal of the American Academy of Child and Adolescent Psychiatry, 52<\/span><\/i>(9), 976\u2013990. https:\/\/www.jaacap.org\/article\/S0890-8567(09)62600-9\/pdf<\/span><\/a>\u00a0<\/span><\/p>\n\ufffc<\/span>\u00a0<\/span><\/p>\nNaber, D., & Lambert, M. (2009). The CATIE and CUtLASS studies in schizophrenia: Results and implications for clinicians. <\/span>CNS Drugs, 23<\/span><\/i>(8), 649\u2013659. https:\/\/doi.org\/10.2165\/00023210-200923080-00002<\/span><\/a>\u00a0<\/span><\/p>\n\u00a0<\/span><\/p>\n\u00a0<\/span><\/p>\nMedication Resources<\/span><\/b>\u202f(click to expand\/reduce)<\/span><\/a>\u00a0<\/span><\/p>\n
According to the Schizophrenia and Related Disorders Alliance of America, approximately 3.5 million people in the United States are diagnosed with schizophrenia (n.d.), and it is one of the leading causes of disability. In practice, patients may present with delusions, hallucinations, disorganized thinking, disorganized or abnormal motor behavior, as well as other negative symptoms that can be disabling for these individuals. Not only are these symptoms one of the most challenging symptom clusters you will encounter, many are associated with other disorders, such as depression, bipolar disorder, and disorders on the schizophrenia spectrum. As a psychiatric nurse practitioner, you must understand the underlying neurobiology of these symptoms to select appropriate therapies and improve outcomes for patients.<\/span>\u00a0<\/span><\/p>\n This week, as you examine antipsychotic therapies, you explore the assessment and treatment of patients with psychosis and schizophrenia. You also consider ethical and legal implications of these therapies.<\/span>\u00a0<\/span><\/p>\n Reference:<\/span> Learning Objectives<\/span>\u00a0<\/span><\/p>\n \u00a0<\/span><\/p>\n Learning Resources<\/span>\u00a0<\/span><\/p>\n \u00a0<\/span><\/p>\n Required Readings<\/span><\/b>\u202f(click to expand\/reduce)<\/span><\/a>\u00a0<\/span><\/p>\n \u00a0<\/span><\/p>\n Freudenreich, O., Goff, D. C., & Henderson, D. C. (2016). Antipsychotic drugs. In T. A. Stern, M. Favo, T. E. Wilens, & J. F. Rosenbaum. (Eds.), <\/span>Massachusetts General Hospital psychopharmacology and neurotherapeutics<\/span><\/i>\u202f(pp. 72\u201385). Elsevier.<\/span>\u00a0<\/span><\/p>\n \u00a0<\/span><\/p>\n American Psychiatric Association. (2019). <\/span>Practice guideline for the treatment of patients with schizophrenia<\/span><\/i>. https:\/\/www.psychiatry.org\/File%20Library\/Psychiatrists\/Practice\/Clinical%20Practice%20Guidelines\/APA-Draft-Schizophrenia-Treatment-Guideline.pdf<\/span><\/a>\u00a0<\/span><\/p>\n \ufffc<\/span>\u00a0<\/span><\/p>\n Clozapine REMS. (2015). <\/span>Clozapine REMS: The single shared system for clozapine<\/span><\/i>. https:\/\/www.clozapinerems.com\/CpmgClozapineUI\/rems\/pdf\/resources\/Clozapine_REMS_A_Guide_for_Healthcare_Providers.pdf<\/span><\/a>\u00a0<\/span><\/p>\n \ufffc<\/span>\u00a0<\/span><\/p>\n Funk, M. C., Beach, S. R., Bostwick, J. R., Celano, C. M., Hasnain, M., Pandurangi, A., Khandai, A., Taylor, A., Levenson, J. L., Riba, M., & Kovacs, R. J. (2018). <\/span>Resource document on QTc prolongation and psychotropic medications<\/span><\/i>. American Psychiatric Association. https:\/\/www.psychiatry.org\/File%20Library\/Psychiatrists\/Directories\/Library-and-Archive\/resource_documents\/Resource-Document-2018-QTc-Prolongation-and-Psychotropic-Med.pdf<\/span><\/a>\u00a0<\/span><\/p>\n \ufffc<\/span>\u00a0<\/span><\/p>\n Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. <\/span>Schizophrenia Bulletin, 13<\/span><\/i>(2), 261\u2013276.\u202fhttps:\/\/doi.org\/10.1093\/schbul\/13.2.261<\/span><\/a>\u00a0<\/span><\/p>\n \ufffc<\/span>\u00a0<\/span><\/p>\n Levenson, J. C., Kay, D. B., & Buysse, D. J. (2015). The pathophysiology of insomnia. <\/span>Chest, 147<\/span><\/i>(4), 1179\u20131192. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4388122\/<\/span><\/a>\u00a0<\/span><\/p>\n \ufffc<\/span>\u00a0<\/span><\/p>\n McClellan, J. & Stock. S. (2013). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. <\/span>Journal of the American Academy of Child and Adolescent Psychiatry, 52<\/span><\/i>(9), 976\u2013990. https:\/\/www.jaacap.org\/article\/S0890-8567(09)62600-9\/pdf<\/span><\/a>\u00a0<\/span><\/p>\n \ufffc<\/span>\u00a0<\/span><\/p>\n Naber, D., & Lambert, M. (2009). The CATIE and CUtLASS studies in schizophrenia: Results and implications for clinicians. <\/span>CNS Drugs, 23<\/span><\/i>(8), 649\u2013659. https:\/\/doi.org\/10.2165\/00023210-200923080-00002<\/span><\/a>\u00a0<\/span><\/p>\n \u00a0<\/span><\/p>\n \u00a0<\/span><\/p>\n Medication Resources<\/span><\/b>\u202f(click to expand\/reduce)<\/span><\/a>\u00a0<\/span><\/p>\n
\nSchizophrenia and Related Disorders Alliance of America. (n.d.).\u202f<\/span>About\u202f schizophrenia<\/span><\/i>.https:\/\/sardaa.org\/resources\/about-schizophrenia\/#:~:text=Quick%20Facts%20About%20Schizophrenia.%20Schizophrenia%20can%20be%20found,is%20one%20of%20the%20leading%20causes%20of%20disability<\/a><\/span>\u00a0<\/span><\/p>\nStudents will:<\/span><\/b>\u00a0<\/span><\/h2>\n
\n